title: Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
abstract: Contrast-enhanced magnetic resonance (MR) imaging with a new liver-specific contrast agent gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid (Gd-EOB-DTPA; EOB·Primovist®) was studied in 14 normal beagles and 9 dogs with focal liver lesions. Gd-EOB-DTPA accumulates in normally functioning hepatocytes 20 min after injection. As with Gd-DTPA, it is also possible to perform a dynamic multiphasic examination of the liver with Gd-EOB-DTPA, including an arterial phase and a portal venous phase. First, a reliable protocol was developed and the appropriate timings for the dynamic study and the parenchymal phase in normal dogs using Gd-EOB-DTPA were determined. Second, the patterns of these images were evaluated in patient dogs with hepatic masses. The optimal time of arterial imaging was from 15 s after injection, and the optimal time for portal venous imaging was from 40 s after injection. Meanwhile, the optimal time to observe changes during the hepatobiliary phase was from 20 min after injection. In patient dogs, 11 lesions were diagnosed as malignant tumors; all were hypointense to the surrounding normal liver parenchyma during the hepatobiliary phase. Even with a low-field MR imaging unit, the sequences afforded images adequate to visualize the liver parenchyma and to detect tumors within an appropriate scan time. Contrast-enhanced MR imaging with Gd-EOB-DTPA provides good demarcation on low-field MR imaging for diagnosing canine focal liver lesions.
authors.affiliation: Department of Small Animal Clinical Sciences, Rakuno Gakuen University, Ebetsu, Hokkaido, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yonetomi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kadosawa
authors.forename: Kenjirou
authors.initials: K
authors.lastname: Miyoshi
authors.forename: Yukie
authors.initials: Y
authors.lastname: Nakao
authors.forename: Emi
authors.initials: E
authors.lastname: Homma
authors.forename: Kiwamu
authors.initials: K
authors.lastname: Hanazono
authors.forename: Eriko
authors.initials: E
authors.lastname: Yamada
authors.forename: Kozo
authors.initials: K
authors.lastname: Nakamura
authors.forename: Atsuki
authors.initials: A
authors.lastname: Ijiri
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Minegishi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Maetani
authors.forename: Kazuko
authors.initials: K
authors.lastname: Hirayama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Taniyama
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nakade
mesh_terms: D000818:Animals; D003287:Contrast Media; D004283:Dog Diseases / Q000175:diagnosis*; D004285:Dogs; D005260:Female; D020518:Focal Nodular Hyperplasia / Q000175:diagnosis / Q000662:veterinary*; D019786:Gadolinium DTPA; D008099:Liver / Q000473:pathology*; D008113:Liver Neoplasms / Q000175:diagnosis / Q000662:veterinary*; D008279:Magnetic Resonance Imaging / Q000662:veterinary*; D008297:Male
chemical_list: D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA